Keating Gillian M
Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand.
Paediatr Drugs. 2015 Oct;17(5):411-21. doi: 10.1007/s40272-015-0146-0.
Darunavir (Prezista®), administered in combination with ritonavir and background antiretroviral therapy, is approved in the USA and the EU for the treatment of HIV-1 infection in pediatric patients aged ≥3 years. Ritonavir-boosted darunavir provided effective virologic suppression in treatment-naïve adolescents with HIV-1 infection, according to the results of the noncomparative, phase II DIONE trial. Ritonavir-boosted darunavir also had sustained efficacy in treatment-experienced children and/or adolescents with HIV-1 infection, according to the results of the noncomparative, phase II DELPHI and ARIEL trials. Ritonavir-boosted darunavir was generally well tolerated in pediatric patients with HIV-1 infection. Although more data are needed in pediatric populations (particularly data comparing darunavir with other antiretroviral agents), ritonavir-boosted darunavir is an important option for the treatment of pediatric patients with HIV-1 infection.
达芦那韦（Prezista®）与利托那韦及背景抗逆转录病毒疗法联合使用，在美国和欧盟被批准用于治疗3岁及以上儿科患者的HIV-1感染。根据非对照的II期DIONE试验结果，利托那韦增强的达芦那韦在初治的HIV-1感染青少年中提供了有效的病毒学抑制。根据非对照的II期DELPHI和ARIEL试验结果，利托那韦增强的达芦那韦在有HIV-1感染治疗经验的儿童和/或青少年中也具有持续疗效。利托那韦增强的达芦那韦在HIV-1感染的儿科患者中总体耐受性良好。尽管儿科人群还需要更多数据（特别是比较达芦那韦与其他抗逆转录病毒药物的数据），但利托那韦增强的达芦那韦是治疗HIV-1感染儿科患者的重要选择。
